131-I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma

嗜铬细胞瘤是一种神经内分泌肿瘤，起源于肾上腺髓质或交感神经节的细胞。这些肿瘤大多数是良性的，但10 - 30%是恶性的，预期寿命为3 - 5年。恶性嗜铬细胞瘤除了手术治疗局部疾病外，目前还没有已知的根治性治疗方法。目前广泛转移性疾病的治疗包括化疗、化疗栓塞、奥曲肽和131 I-MIBG。一般来说，这些治疗是姑息性的，但很少有患者有完全的反应 该项目测试使用131 I-MIBG放射毒性治疗恶性嗜铬细胞瘤的疗效，特别是测试使用特定药物（所谓的增敏剂）进行预治疗是否会增加131 I-MIBG治疗的疗效。最近，该协议已被搁置，以寻找一个实验室，将提供给我们131 I-MIBG。

Pheochromocytomas are neuroendocrine tumors that develop from cells in the adrenal medulla or sympathetic ganglion. Most of these tumors are benign but 10 to 30% are malignant with life expectancy ranging 3 to 5 years. Other than surgery for local disease, there is no known curative treatment for malignant pheochromocytoma. Current therapies for widespread metastatic disease include chemotherapy, chemoembolization, octreotide, and 131I-MIBG. In general these treatments are palliative but very few patients have had complete responses This project tests the efficacy of radiotoxic treatment of malignant pheochromocytoma using 131I-MIBG, and in particular tests whether pre-treatment using specific drugs (so called sentitizers) increases the efficacy of 131I-MIBG treatment. Recently, the protocol has been on hold to find a laboratory that will supply us with 131I-MIBG.